Ceftobiprole Perspective: Current and Potential Future Indications

Lupia, Tommaso; Pallotto, Carlo; Corcione, Silvia; Boglione, Lucio; Rosa, Francesco Giuseppe De

doi:10.3390/antibiotics10020170

Cited by 22 publications

(14 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ceftobiprole is susceptible to degradation by ESBLs, AmpC, and Class A, Class B and Class D carbapenemases. Ceftobiprole is approved for community and hospital acquired pneumonia and skin and soft-tissue infections, including diabetic foot infections [109,110].…”

Section: Overcoming Resistance Through Novel Antibioticsmentioning

confidence: 99%

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions

et al. 2021

View full text Add to dashboard Cite

Multidrug-resistant bacteria have on overwhelming impact on human health, as they cause over 670,000 infections and 33,000 deaths annually in the European Union alone. Of these, the vast majority of infections and deaths are caused by only a handful of species—multi-drug resistant Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus spp., Acinetobacter spp. and Klebsiella pneumoniae. These pathogens employ a multitude of antibiotic resistance mechanisms, such as the production of antibiotic deactivating enzymes, changes in antibiotic targets, or a reduction of intracellular antibiotic concentration, which render them insusceptible to multiple antibiotics. The purpose of this review is to summarize in a clinical manner the resistance mechanisms of each of these 6 pathogens, as well as the mechanisms of recently developed antibiotics designed to overcome them. Through a basic understanding of the mechanisms of antibiotic resistance, the clinician can better comprehend and predict resistance patterns even to antibiotics not reported on the antibiogram and can subsequently select the most appropriate antibiotic for the pathogen in question.

show abstract

Section: Overcoming Resistance Through Novel Antibioticsmentioning

confidence: 99%

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions

et al. 2021

View full text Add to dashboard Cite

show abstract

“…23 When creatinine clearance (CrCl) is greater than 150 mL/min, extending infusion time to 4 hours is required to keep plasma levels above the minimum inhibitory concentration (MIC). 24 25 Ceftobiprole has demonstrated a good safety profile, and the most common adverse events (AEs) with ceftobiprole include headache, nausea, diarrhea, vomiting, infusion-site reactions, dysgeusia, and drug-related hypersensitivity. 26 In a 2010 study, no measurable concentrations of ceftobiprole were detected in feces following intravenous (IV) administration in healthy volunteers and no Clostridioides difficile strains or toxins were found.…”

Section: Approved Antibiotics For the Treatment Of Hap And Vapmentioning

confidence: 99%

New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Bassetti

Mularoni

Giacobbe

et al. 2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent one of the most common hospital-acquired infections, carrying a significant morbidity and risk of mortality. Increasing antibiotic resistance among the common bacterial pathogens associated with HAP and VAP, especially Enterobacterales and nonfermenting gram-negative bacteria, has made the choice of empiric treatment of these infections increasingly challenging. Moreover, failure of initial empiric therapy to cover the causative agents associated with HAP and VAP has been associated with worse clinical outcomes. This review provides an overview of antibiotics newly approved or in development for the treatment of HAP and VAP. The approved antibiotics include ceftobiprole, ceftolozane–tazobactam, ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, and cefiderocol. Their major advantages include their high activity against multidrug-resistant gram-negative pathogens.

show abstract

“…Omadacycline (a cycline alternative), lefamulin (the first pleuromutilin), solithromycin (macrolide), nemonoxacin (quinolone) and delafloxacin/zabofloxacin (both fluoroquinolones) are other agents worth mentioning however not yet approved for the treatment of sCAP. Table 3 summarizes the major features of these new drugs for the treatment of CAP in critically ill patients [37,[52][53][54][55][56].…”

Section: Role Of Novel Antibiotics In Icu Settingsmentioning

confidence: 99%

Choosing antibiotic therapy for severe community-acquired pneumonia

Martín‐Loeches

Garduno

Póvoa

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewCommunity-acquired pneumonia (CAP) is known as a major worldwide health concern considering it has been shown to account for 78% of infection-related deaths in the USA. It is a common cause for hospitalization with a continued incidence rise in the elderly, high mortality rate and long-term sequelae in critically ill patients. Severe CAP (sCAP) is an accepted terminology used to describe ICU admitted patients with CAP. The aim of this review is to further report on the major advances in treatment for patients with sCAP including new antibiotic treatments despite macrolide resistance as seen in the ICU, and multifaceted antibiotic stewardship interventions that may lead to the reduction broad-spectrum antibiotic use in CAP. Recent findingsWe aim to examine the most recent findings in order to determine appropriate empirical antibiotic choices, timing regimens and evidence for clinical effectiveness. This will be addressed by focusing on the use combination therapies, the usefulness of severity scores and the difficulty to treat multidrug-resistant pathogens, including gram negatives such as Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Relevant reports referenced within included randomized controlled trials, metaanalyses, observational studies, systematic reviews and international guidelines where applicable. SummaryNew antibiotics have been recently launched with direct agent-specific properties that have been shown to avoid the overuse of previous broad-spectrum antibiotics when treating patients sCAP. Although narrowspectrum antibiotics are now recommended and imperative in improving a patients' prognosis, there are also some considerations when prescribing antibiotics that are beyond the spectrum. There is a need to implement effective policies of de-escalation to avoid antibiotic resistance and the risk for developing subsequent infections by combining informed clinical judgement and the application of biomarkers. Reaching clinical stability and avoidance of treatment failure are the most important pillars in treatment success.

show abstract

Ceftobiprole Perspective: Current and Potential Future Indications

Cited by 22 publications

References 64 publications

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions

New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Choosing antibiotic therapy for severe community-acquired pneumonia

Contact Info

Product

Resources

About